Adherex Reports Feedback From the FDA From End of Phase 2 Meeting

By admin Research Triangle Park, NC, May 23, 2013 – Adherex Technologies Inc. (TSX:AHX, OTCQB: ADHXF), today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer (MBC) patients who had rapid disease progression on capecitabine. […]

Scroll to Top